May 2nd 2024
Investigators will begin setting up the TRANSFORM trial in spring 2024, with study recruitment set to begin later in the year
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
How the Experts Treat NMIBC During a BCG Shortage—Integrating Recent Approvals and Investigational Therapies
View More
Staying Abreast of the Prostate Cancer Treatment Paradigm From Risk Stratification to Adaptive Sequencing Strategies
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Medical Crossfire®: How Will Emerging Data Inform Treatment Planning for Patients With Prostate Cancer in the Community?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Urology Perspective on Radiation Toxicity in Prostate Cancer
Urologists offer their perspectives on toxicity seen in patients with prostate cancer who are undergoing radiation treatment.
Radiation Safety Considerations for Patients With Prostate Cancer
Experts on prostate cancer discuss the risks, complications, and safety considerations for patients with prostate cancer who are considering radiation therapy.
Recommendations for the Use of Rectal Spacers in Clinical Practice for Patients With Prostate Cancer
November 21st 2023Dr Hamstra recommends rectal spacers in certain prostate cancer patients to reduce rectal toxicity, allow dose escalation, and preserve sexual function, but advises judicious use due to potential complications and lack of long-term quality of life data with newer spacers.
Black men have higher risk of prostate cancer at any PSA level
November 14th 2023“These findings suggest that to reduce health disparities for Veterans in the prevention of prostate cancer, clinicians should consider an individual Veteran’s risk for prostate cancer including factors such as race and age," says Kyung Min Lee, PhD.
Study: Lower PCSM is seen with radical prostatectomy vs other modalities
November 14th 2023"This large registry study with data from varied practice settings, incorporating the most commonly used treatment modalities, provides useful data on the long-term mortality outcomes," writes Badar M. Mian, MD.
Rectal Separation for Prostate Cancer Radiation Therapy: Clinical Data on Barrigel and BioProtect
November 14th 2023The Phase 3 trials for the Barrigel and BioProtect rectal spacers demonstrated a dosimetric advantage and reduced rectal toxicity similar to SpaceOAR, but data on long-term toxicity and patient-reported outcomes is still needed to fully evaluate the newer spacers.
Comparing Leuprolide Formulations in Advanced Prostate Cancer
November 13th 2023In the third article of the series, Melanie McGilloway, NP-C, an advanced practice provider at Genesis Urology in San Diego, discusses the various formulations of leuprolide, a gonadotropin-releasing hormone (GnRH) agonist used for treating advanced prostate cancer.
Dr. Lowentritt on future directions in the management of prostate cancer
November 10th 2023"The biggest thing that we're seeing in prostate cancer now, and I think will continue to evolve, is really getting into narrowing our different types and stratifying patients differently," says Benjamin H. Lowentritt, MD, FACS.
Rectal Separation for Prostate Cancer Radiation Therapy: Clinical Data on SpaceOAR and SpaceOAR Vue
November 7th 2023The SpaceOAR rectal spacer phase 3 trial showed reduced toxicity and improved quality of life, leading to FDA approval, but device-related side effects have emerged with broader clinical use.
Available Rectal Spacer Options for Patients With Prostate Cancer Undergoing Radiation Therapy
November 7th 2023Dr Hamstra describes the three FDA-approved rectal spacers SpaceOAR, Barrigel, and BioProtect, noting differences in placement technique, advantages, potential risks, and the need for long-term clinical data on patient outcomes.
Overcoming Barriers to Triplet Therapy in Prostate Cancer
November 1st 2023Join experts David Morris, MD, FACS, and Benjamin Garmezy, MD, as they discuss the barriers and considerations in prescribing triplet therapy, offering insight into its benefits and how collaborative care between urologists and medical oncologists ensures a seamless patient journey.
Enhancing Efficacy in Advanced Hormone-Sensitive Prostate Cancer Treatment
November 1st 2023Join key opinion leaders as they analyze the evolving landscape of metastatic HSPC, delving into the advantages and key factors to consider with triplet combination therapies, encompassing chemotherapy and ARPI agents.